These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2869745)

  • 1. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine.
    Tamminga CA; Gotts MD; Thaker GK; Alphs LD; Foster NL
    Arch Gen Psychiatry; 1986 Apr; 43(4):398-402. PubMed ID: 2869745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia.
    Lahti AC; Weiler MA; Corey PK; Lahti RA; Carlsson A; Tamminga CA
    Biol Psychiatry; 1998 Jan; 43(1):2-11. PubMed ID: 9442338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine's antipsychotic activity.
    Schaffer MH; Davis JM; Tamminga CA
    Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
    Merello M; Starkstein S; Petracca G; Cataneo EA; Manes F; Leiguarda R
    Clin Neuropharmacol; 1996 Oct; 19(5):439-43. PubMed ID: 8889287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenic symptoms improve with apomorphine.
    Tamminga CA; Schaffer MH; Smith RC; Davis JM
    Science; 1978 May; 200(4341):567-8. PubMed ID: 347574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Jones BD; Annable L
    Am J Psychiatry; 1978 Nov; 135(11):1409-10. PubMed ID: 30291
    [No Abstract]   [Full Text] [Related]  

  • 10. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic-like and antipsychotic effects of gamma-type endorphins.
    Van Ree JM; Verhoeven WM; Van Praag HM; De Wied D
    Mod Probl Pharmacopsychiatry; 1981; 17():266-78. PubMed ID: 6173744
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G; Annable L; Jones BD; Collu R
    Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H; Hillert A; Gründer G; Benkert O
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.
    van Kammen DP
    Psychol Med; 1991 Nov; 21(4):881-95. PubMed ID: 1685791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
    Chouinard G; Jones BD
    Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in [3H]-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients.
    Grodzicki J; Pardo M; Schved G; Schlosberg A; Fuchs S; Kanety H
    Biol Psychiatry; 1990 Jun; 27(12):1327-30. PubMed ID: 1973057
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.